Subcutaneous Cardiac Monitoring of Patients With BTK Inhibitors

Inclusion Criteria:

• Adult patients,
• Definite diagnosis of hematologic malignancy requiring a BTK inhibition withibrutinib, acalabrutinib or zanubrutinib,
• Expected BTK inhibitor duration estimated to be at least 12 months,
• Sinus rhythm at enrolment,
• Willing to sign patient consent form and to comply with scheduled visits, as outlinedin the protocol

Exclusion Criteria:

• Age < 18 years old,
• Adults with protective measures (curatorship or tutorship) and vulnerable patients,
• Pregnant or nursing women,
• Permanent atrial fibrillation or long-standing persistent atrial fibrillation asdefined by the European Society of Cardiology guidelines,
• Atrial fibrillation on the electrocardiogram at the inclusion visit,
• Previous left atrial ablation or previous maze or maze-like surgery,
• Indication for or patients with a pacemaker or implantable cardioverter-defibrillatorat baseline,
• Untreated hyperthyroidism,
• Uncorrected kaliaemia disorders at the inclusion visit,
• Hemoglobin < 8 g/L at the inclusion visit,
• Thrombopenia < 50,000/mm3 at the inclusion visit,
• Active bleeding,
• Myocardial infarction < 1 month,
• Surgery < 1 month,
• Mechanical heart valve,
• Valvular heart disease requiring surgery,
• Inability to follow the required procedures of the clinical investigation plan,
• No signature of patient consent form.